| 黄孟芹,胡丽霞,储小凤.全身化疗同步应用谷胱甘肽对转移性肝癌肝脏功能的保护作用及安全性分析[J].安徽医药,2019,23(11):2279-2282. |
| 全身化疗同步应用谷胱甘肽对转移性肝癌肝脏功能的保护作用及安全性分析 |
| liver cancer and its safety analysis |
| |
| DOI：10.3969/j.issn.1009?6469.2019.11.042 |
| 中文关键词: 肝肿瘤 谷胱甘肽 肿瘤转移 抗肿瘤联合化疗方案 生存获益 |
| 英文关键词: Liver neoplasms Glutathione Neoplasm metastasis Antineoplastic combined chemotherapy protocols Survival benefit |
| 基金项目: |
|
| 摘要点击次数: 2225 |
| 全文下载次数: 720 |
| 中文摘要: |
| 目的探究全身化疗同步应用谷胱甘肽对转移性肝癌病人肝脏功能的保护作用及其安全性。方法选取 2015年 1月到 2017年 10月合肥市第二人民医院收治的转移性肝癌病人 40例，所有病人均接受全身化疗，按照随机数字表法将病人分为对照组 20例，采用同步常规对症治疗；观察组 20例，在对照组病人治疗的基础上联合还原型谷胱甘肽静脉滴注治疗。所有病人在院均行影像学、肝功能等相关检查，化疗 2程后再次检查相关指标，比较两组治疗前后临床症状改善情况、肝功能差异以及不良反应发生情况。结果观察组上腹不适好转率( 90.0%)、消化功能紊乱好转率( 95.00%)、乏力好转率( 90.00%)以及纳差好转率( 95.00%)均明显高于对照组( 55.00%、65.00%、60.00%、60.00%)差异有统计学意义( P＜0.05)。两组治疗前血清丙氨酸氨基转移酶( ALT)、天冬氨酸氨基转移酶( AST)、谷氨酰转肽酶( GGT)、总，胆红素( TBil)水平均差异无统计学意义( P＞0.05)。经过不同方案治疗后，观察组病人 ALT(20.20±10.46)U/L、AST(27.90±20.48)U/L、GGT(84.80±67.48)U/L、TBil水平( 15.00± 8.06)μmol/L明显低于治疗前［(26.20±6.70)U/L、(40.05±17.22)U/L、(128.25±66.63)U/L、(15.27±7.04)μmol/L］，均差异有统计学意义( P＜0.05)。观察组病人血清 ALT、AST、GGT水平改善总有效率明显高于对照组，差异有统计学意义( P＜0.05)；两组病人 TBil改善效果差异无统计学意义( P＞0.05)。结论全身化疗同步应用谷胱甘肽对转移性肝癌病人肝脏功能的保护作用显著，且使用安全，提升化疗依从性，使生存获益，值得在临床推广应用。 |
| 英文摘要: |
| Objective To investigate the protective effect and safety of systemic chemotherapy and concurrent application of gluta?thione on liver function in patients with metastatic liver cancer.Methods The study participants selected 40 patients with metastat?ic liver cancer who were admitted to the Second People’s Hospital from January 2015 to October 2017.All patients were receivedsystemic chemotherapy.20 patients with synchronous conventional hepatoprotective therapy were selected as the control group and20 patients were in the control group.On the basis of treatment，patients treated with combined reduction of glutathione were treatedas observation groups.All patients were hospitalized for iconography，liver function and other related examinations，and related indi? cators were examined again after twocycles of chemotherapy.The improvement of clinical symptoms，differences in liver function， and occurrence of adverse reactions before and after treatment were compared between the two groups.Results The improvement rate of upper abdominal discomfort(90.0% vs. 55.00%)，disorders of digestion(95.00% vs. 65.00%)，fatigue(90.00% vs. 60.00%) and(95.00% vs. 60.00%)nadir were all significantly higher in the observation group than in the control group.The difference was statistically significant(P＜0.05).There was no significant difference in serum ALT，AST，GGT and TBil levels before treatment be? tween the two groups(P＞0.05).After treatment with different regimens，the levels of ALT［(20.20±10.46)U/L vs.(26.20±6.70)U/ L］，AST［(27.90±20.48)U/L vs.(40.05±17.22)U/L］，GGT［(84.80±67.48)U/L vs.(128.25±66.63)U/L］，and TBil［(15.00±8.06) μmol/L vs.(15.27±7.04)μmol/L］in the observation group were significantly lower than before treatment.Statistically significant(P＜ 0.05).After hepatoprotective therapy with different regimens，the total effective rate of serum ALT，AST，and GGT levels in the ob? servation group was significantly higher than that in the control group(P＜0.05).The improvement effect of TBil in the two groups was not statistically significant(P＞0.05).Conclusion The simultaneous application of systemic chemotherapy to glutathione hasa significant protective effect on hepatic function in patients with m，which is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
